Immune thrombocytopenic purpura (ITP) is an autoimmune disorder that leads to a decline in platelet production, thus increasing the risk of bleeding. Current therapies for ITP can be broadly divided into immunomodulators, thrombopoietin receptor agonists (TPO–RAs), and spleen tyrosine kinase inhibitors (Syk inhibitors). Systemic glucocorticoids and TPO–RAs are the cornerstones of clinical management; however, the Syk inhibitor fostamatinib (Rigel Pharmaceuticals’ Tavalisse) and biologics such as rituximab provide additional options for refractory disease. This report offers insights from real-world claims data into prescribing trends for ITP to help new players better understand current treatment practices that may define the market niche for their emerging product.
Questions answered
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Amgen, Novartis, Rigel Pharmaceuticals, Sobi
Key drugs: Antibiotics, avatrombopag (Doptelet), eltrombopag (Promacta), fostamatinib (Tavalisse), rituximab (Rituxan, biosimilars), romiplostim (Nplate), systemic glucocorticoids
Key features
Dashboard featuring interactive visuals, easy navigation, and expanded analyses.